ArticleJournal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
Retrospective Determination of the Incidence of Apparent Type I Hypersensitivity Reaction to Intravenous Amoxicillin-Clavulanate in Dogs and Cats.
Article in Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RECOVER Guidelines: First Aid. Evidence, Treatment Recommendations, Knowledge Gap Analysis, and Clinical Guidelines for Acute Allergy and Anaphylaxis in Dogs and Cats.Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the incidence of, and characterize the clinical signs associated with, apparent type I hypersensitivity (HS) reactions due to administration of a new formulation of IV amoxicillin-clavulanate (AC).
designObservational retrospective study.
settingTwo private specialty hospitals in New South Wales, Australia. ANIMALS: One thousand six hundred seventy-two dogs and cats administered a new formulation of IV AC. MEASUREMENTS AND MAIN
resultsBetween September 2018 and May 2022, patients were identified that received chlorpheniramine or dexamethasone within 6 h of receiving the new formulation of IV AC, had an allergy alert to the new formulation noted in the medical record, or had an allergy or suspected reaction to the new formulation described in the medical record. Patients were included if the new formulation was administered, if they had evidence of a type I HS reaction within 6 h of injection, and if they were administered treatment for a type I HS reaction. Eleven dogs (and no cats) had an apparent type I HS reaction (incidence 0.81% for dogs). Cases were clustered between November 2021 and May 2022 (n = 10), with an incidence of 2.13% for dogs. Dermatologic signs were recorded for all cases (n = 11), with some showing cardiovascular (n = 2) or gastrointestinal signs (n = 1). All cases survived.
conclusionsThe incidence of a type I HS reaction to the new formulation of IV AC in dogs was low, and the outcome was excellent. No reactions in cats were identified. A cause for clustering of cases within a 6-month period was not elucidated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.